Next Article in Journal
Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications
Next Article in Special Issue
Beyond Genetics—Stratified and Personalised Medicines Using Multiple Parameters
Previous Article in Journal
Ingested Type I Interferon—State of the Art as Treatment for Autoimmunity Part 2
Previous Article in Special Issue
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
Open AccessReview

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Oxford Road, Manchester, M13 9WL, UK
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(4), 1122-1138;
Received: 30 December 2009 / Revised: 12 March 2010 / Accepted: 9 April 2010 / Published: 15 April 2010
(This article belongs to the Special Issue Personalized Medicine)
Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy. View Full-Text
Keywords: tamoxifen; CYP2D6 genotyping; breast cancer tamoxifen; CYP2D6 genotyping; breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Ferraldeschi, R.; Newman, W.G. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals 2010, 3, 1122-1138.

AMA Style

Ferraldeschi R, Newman WG. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals. 2010; 3(4):1122-1138.

Chicago/Turabian Style

Ferraldeschi, Roberta; Newman, William G. 2010. "The Impact of CYP2D6 Genotyping on Tamoxifen Treatment" Pharmaceuticals 3, no. 4: 1122-1138.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop